Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pall, M.
Right arrow Articles by Brännström, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pall, M.
Right arrow Articles by Brännström, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 7, 1323-1328, July 2001
© 2001 European Society of Human Reproduction and Embryology

Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study

Marita Pall,1, Barbro E. Fridén and Mats Brännström

Department of Obstetrics and Gynaecology, Göteborg University, Sahlgrenska University Hospital, S-41345 Göteborg, Sweden

BACKGROUND: The aims of the present study were to examine whether periovulatory administration of a cyclo-oxygenase (COX)-2 inhibitor affects human ovulation and endocrine parameters. METHODS: Thirteen healthy women, 30–40 years of age, without hormonal treatment and with regular menstrual cycles (27–34 days), were given the selective COX-2 inhibitor rofecoxib (n = 6) or placebo (n = 7) in a random double-blind fashion. In an initial control cycle, serial hormonal analyses, detection of a measurable mid-cycle urine LH peak and transvaginal ultrasound scans were performed to confirm normal ovulatory and endocrinological cyclic patterns, in all participating women. During the subsequent treatment cycle, serial ultrasound scans were performed. When the dominant follicle reached 14–16 mm in diameter, 25 mg rofecoxib or placebo was taken orally, once daily for 9 consecutive days, during which follicle size was monitored daily by ultrasound scans and serial hormone analyses were performed. RESULTS: Four of the six women who received rofecoxib demonstrated delayed follicle rupture, >48 h after the LH peak, when compared with the placebo group, who all had follicular rupture >36 h after the detected LH peak. No differences in peripheral serum concentrations of progesterone, oestradiol, LH and FSH were observed between placebo and rofecoxib groups, when analysed at specified time intervals. CONCLUSIONS: This study suggests that selective COX-2 inhibition has a negative, local effect on human ovulation, resulting in delayed follicular rupture, without affecting peripheral hormonal cyclicity.

Key words: cyclooxygenase/ovary/ovulation/prostaglandin/rofecoxib

1 To whom correspondence should be addressed. E-mail: mspall{at}hotmail.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EndocrinologyHome page
N. Markosyan and D. M. Duffy
Prostaglandin E2 Acts via Multiple Receptors to Regulate Plasminogen-Dependent Proteolysis in the Primate Periovulatory Follicle
Endocrinology, January 1, 2009; 150(1): 435 - 444.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
T. L. Tootle and A. C. Spradling
Drosophila Pxt: a cyclooxygenase-like facilitator of follicle maturation
Development, March 1, 2008; 135(5): 839 - 847.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
D. L. Russell and R. L. Robker
Molecular mechanisms of ovulation: co-ordination through the cumulus complex
Hum. Reprod. Update, May 1, 2007; 13(3): 289 - 312.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M.R. Massai, M.L. Forcelledo, V. Brache, A.S. Tejada, A.M. Salvatierra, M.V. Reyes, F. Alvarez, A. Faundes, and H.B. Croxatto
Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study
Hum. Reprod., February 1, 2007; 22(2): 434 - 439.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
Y. L. Pon and A. S. T. Wong
Gonadotropin-Induced Apoptosis in Human Ovarian Surface Epithelial Cells Is Associated with Cyclooxygenase-2 Up-Regulation via the {beta}-Catenin/T-Cell Factor Signaling Pathway
Mol. Endocrinol., December 1, 2006; 20(12): 3336 - 3350.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
N. Markosyan, B. L. Dozier, F. A. Lattanzio, and D. M. Duffy
Primate Granulosa Cell Response via Prostaglandin E2 Receptors Increases Late in the Periovulatory Interval
Biol Reprod, December 1, 2006; 75(6): 868 - 876.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. Wang, S. K. Dey, and M. Maccarrone
Jekyll and Hyde: Two Faces of Cannabinoid Signaling in Male and Female Fertility
Endocr. Rev., August 1, 2006; 27(5): 427 - 448.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
M. S. Bata, M. Al-Ramahi, A. S. Salhab, M. N. Gharaibeh, and J. Schwartz
Delay of Ovulation by Meloxicam in Healthy Cycling Volunteers: A Placebo-Controlled, Double-blind, Crossover Study.
J. Clin. Pharmacol., August 1, 2006; 46(8): 925 - 932.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
D. M. Duffy, C. L. Seachord, and B. L. Dozier
Microsomal prostaglandin E synthase-1 (mPGES-1) is the primary form of PGES expressed by the primate periovulatory follicle
Hum. Reprod., June 1, 2005; 20(6): 1485 - 1492.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
C. L. Seachord, C. A. VandeVoort, and D. M. Duffy
Adipose Differentiation-Related Protein: A Gonadotropin- and Prostaglandin-Regulated Protein in Primate Periovulatory Follicles
Biol Reprod, June 1, 2005; 72(6): 1305 - 1314.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Symowicz, B. P. Adley, M. M.M. Woo, N. Auersperg, L. G. Hudson, and M. S. Stack
Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells
Cancer Res., March 15, 2005; 65(6): 2234 - 2242.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. Sirois, K. Sayasith, K. A. Brown, A. E. Stock, N. Bouchard, and M. Dore
Cyclooxygenase-2 and its role in ovulation: a 2004 account
Hum. Reprod. Update, September 1, 2004; 10(5): 373 - 385.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
M. W. Peters, J. R. Pursley, and G. W. Smith
Inhibition of intrafollicular PGE2 synthesis and ovulation following ultrasound-mediated intrafollicular injection of the selective cyclooxygenase-2 inhibitor NS-398 in cattle
J Anim Sci, June 1, 2004; 82(6): 1656 - 1662.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
T. D. WARNER and J. A. MITCHELL
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
FASEB J, May 1, 2004; 18(7): 790 - 804.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. R. Smith, M. B. Daly, and X.-X. Xu
A Mechanism for Cox-2 Inhibitor Anti-Inflammatory Activity in Chemoprevention of Epithelial Cancers
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 144 - 145.
[Full Text] [PDF]


Home page
Hum ReprodHome page
D. M. Duffy and R. L. Stouffer
Follicular administration of a cyclooxygenase inhibitor can prevent oocyte release without alteration of normal luteal function in rhesus monkeys
Hum. Reprod., November 1, 2002; 17(11): 2825 - 2831.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.